Uzan, Gamze SarıkayaVural, AtayYüksel, DenizAksoy, ErhanÖztoprak, ÜlkühanCanpolat, MehmetÖztürk, SelcanYıldırım, ÇelebiGüleç, AytenPer, HüseyinGümüş, HakanOkuyaz, ÇetinDirek, Meltem ÇobanoğullarıKosmür, MustafaÜnalp, AycanYılmaz, ÜnsalBektas, ÖmerTeber, SerapAliyeva, NargizDündar, Nihal OlgaçGençpınar, PınarGürkaş, EsraYılmaz, Sanem KeskinKanmaz, SedaTekgtil, HasanAksoy, AyşeTuncer, Gökcen ÖzArslan, Elif AcarTosun, AyşeKızılırmak, Ali BurakYousefi, MohammadrezaÜnay, BülentKurul, Semra HizYis, Uluç2024-12-042024-12-042023-05-260887-8994https://doi.org/10.1016/j.pediatrneurol.2023.04.018https://hdl.handle.net/11452/48852Background: To evaluate the clinical features, demographic features, and treatment modalities of pediatric-onset chronic inflammatory demyelinating polyneuropathy (CIDP) in Turkey. Methods: The clinical data of patients between January 2010 and December 2021 were reviewed retrospectively. The patients were evaluated according to the Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society Guideline on the management of CIDP (2021). In addition, patients with typical CIDP were divided into two groups according to the first-line treatment modalities (group 1: IVIg only, group 2: IVIg + steroid). The patients were further divided into two separate groups based on their magnetic resonance imaging (MRI) characteristics. Results: A total of 43 patients, 22 (51.2%) males and 21 (48.8%) females, were included in the study. There was a significant difference between pretreatment and post-treatment modified Rankin scale (mRS) scores (P < 0.05) of all patients. First-line treatments include intravenous immunoglobulin (IVIg) (n = 19, 4 4.2%), IVIg + steroids (n = 20, 46.5%), steroids (n = 1, 2.3%), IVIg + steroids + plasmapheresis (n = 1, 2.3%), and IVIg + plasmapheresis (n = 1, 2.3%). Alternative agent therapy consisted of azathioprine (n = 5), rituximab (n = 1), and azathioprine + mycophenolate mofetil + methotrexate (n = 1). There was no difference between the pretreatment and post-treatment mRS scores of groups 1 and 2 (P > 0.05); however, a significant decrease was found in the mRS scores of both groups with treatment (P < 0.05). The patients with abnormal MRI had significantly higher pretreatment mRS scores compared with the group with normal MRI (P < 0.05). Conclusions: This multicenter study demonstrated that first-line immunotherapy modalities (IVIg vs IVIg + steroids) had equal efficacy for the treatment of patients with CIDP. We also determined that MRI features might be associated with profound clinical features, but did not affect treatment response.eninfo:eu-repo/semantics/closedAccessPolyradiculoneuropathyFeaturesImmunotherapyDiagnosisChildrenNervesCidpMriChronic inflammatory demyelinatingPolyneuropathyChildhoodImmunotherapyIvigSteroidsNeurofascin antibodiesScience & technologyLife sciences & biomedicineClinical neurologyPediatricsNeurosciences & neurologyArticle00102699420000131014510.1016/j.pediatrneurol.2023.04.018